Bal Pharma enters Japanese drug market
Indian drugmaker Bal Pharma has announced its entry into the $60.0 billion Japanese pharmaceutical market. Bal chief executive Shailesh Siroya said that the company has been granted Foreign Manufacturers Accreditation by the Ministry of Health, Labor and Welfare, which is valid for an initial period of five years and is renewable.
He went on to say that two of the Bangalore-headquartered firm's bulk drug products, ebastine, which is used in the production of antihistamines, and the antidiabetic agent gliclazide, have received entry to the Japanese Drug Master File.
Mr Siroya added that Bal, which has three production facilities and an R&D center in India, plans to file for 12 more DMF's over the next three years, which will include submissions for some products specifically formulated for the Japanese market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze